Verichip Corporation: Unique Health Products and Security Identification

Verichip develops unique medical devices and biological detection systems focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MicroFluidic Systems or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays. Verichip Corporation was formed on November 10, 2009 through the merger of Verichip Corporation and Steel Vault Corporation.

Verichip operates in two main divisions: HealthID and MicroFluidic Systems. The HealthID division develops unique medical devices, focused primarily on Erectile Dysfunction and BPH management. Its MicroFluidic Systems subsidiary develops airborne bio-threat detection systems and rapid clinical diagnostic systems.

Basically, there are only three FDA-approved drugs to manage the symptoms of ED. In 1998, sildenafil citrate (generic Viagra) became the first approved oral medication and began a revolution in the field of ED treatment. This drug is well-known under the brand name Viagra and had been exclusively produced by the patent holding company up until recently. Vardenafil was introduced later under the brand name of generic Levitra while tadalafil was approved in 2003 and is known as generic Cialis.

We offer certified generic medications. We only sell drugs that have been approved by the FDA. We’ll help you save on your prescription medications, and we also have an extensive choice of over-the-counter medicines.

In May 2011, Verichip acquired California-based MicroFluidic Systems, founded in 2001, which specializes in the development and production of automated instruments for detecting and processing biological samples. MFS’ core technology is used for airborne pathogen detection, rapid clinical diagnostics and sample preparation applications.

MFS’ microfluidic technology alleviates all existing problems by replacing robotics with integrated microfluidics, reducing cost and increasing reliability. Its microfluidic technology also automates and increases the effectiveness of key sample processing steps used today on the laboratory bench-top, into a closed, automated system. The embedded devices perform cell lysis (including difficult spores) in less than one minute at low power, nucleic acid purification along with inhibitor removal and pre-concentration of the nucleic acids up to factors of 1000X within minutes. These processes all occur autonomously within a fully contained disposable microfluidic cartridge.